Results 21 to 30 of about 158,388 (335)

Adalimumab for induction of remission in Crohn's disease

Cochrane Database of Systematic Reviews, 2017
Adalimumab is an IgG1 monoclonal antibody that targets and blocks tumor necrosis factor-alpha, a pro-inflammatory cytokine involved in the pathogenesis of Crohn's disease (CD). A significant proportion of people with CD fail conventional therapy or therapy with biologics or develop significant adverse events.
Brian G. Feagan, Vipul Jairath, Mohamad Abbass, Claire E Parker, Tran M Nguyen, Jeremy Cepek, Reena Khanna, John K MacDonald   +7 more
openaire   +4 more sources

An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation

Haematologica, 2016
Up to 30% of adults with acute myeloid leukemia fail to achieve a complete remission after induction chemotherapy - termed primary refractory acute myeloid leukemia.
Paul Ferguson, Robert K. Hills, Angela Grech, Sophie Betteridge, Lars Kjeldsen, Michael Dennis, Paresh Vyas, Anthony H. Goldstone, Donald Milligan, Richard E. Clark, Nigel H. Russell, Charles Craddock   +11 more
doaj   +1 more source

Efficacy of adalimumab as second-line therapy in a pediatric cohort of crohn’s disease patients who failed infliximab therapy: The Italian society of pediatric gastroenterology, hepatology, and nutrition experience [PDF]

, 2019
Background: Adalimumab (Ada) treatment is an available option for pediatric Crohn’s disease (CD) and the published experience as rescue therapy is limited.
Accomando S., Aloi M., Alvisi P., Arrigo S., Balzani L., Cucchiara S., De Giacomo C., Gennari M., Guariso G., Knafelz D., Lionetti P., Martelossi S., Miele E., Ravelli A., Romano C., Zuin G.   +15 more
core   +1 more source

Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial

Arthritis Research & Therapy, 2018
Background The aim was to analyze characteristics that predict remission induction and subsequent loss of remission in patients with moderately active rheumatoid arthritis (RA) who received full-dose combination etanercept plus methotrexate induction ...
Josef S. Smolen, Annette Szumski, Andrew S. Koenig, Thomas V. Jones, Lisa Marshall   +4 more
doaj   +1 more source

End of induction treatment outcomes with a novel cyclophosphamide-based regimen for severe lupus nephritis: Single-center experience from South India

Indian Journal of Rheumatology, 2020
Background: Cyclophosphamide is commonly used along with pulse steroids for induction immunosuppression treatment of severe forms of lupus nephritis (LN).
V Jayaprakash, T Dineshkumar, J Dhanapriya, D Rajasekar, R Sakthirajan, T Balasubramaniyan, Anila A Kurien, N Gopalakrishnan   +7 more
doaj   +1 more source

Prevalence and predictors of sustained remission/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review

Arthritis Research & Therapy, 2023
Background To determine the prevalence of sustained remission/low disease activity (LDA) in patients with rheumatoid arthritis (RA) after discontinuation of tumor necrosis factor inhibitors (TNFi), separately in induction treatment and maintenance ...
Michael M. Ward, Nima Madanchi, Ali Yazdanyar, Nehal R. Shah, Florina Constantinescu   +4 more
doaj   +1 more source

Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis

The Saudi Journal of Gastroenterology, 2017
Background/Aims: Treatment of refractory ulcerative colitis (UC) is a clinical challenge, and after biological therapy, monitoring clinical and endoscopic responses is fundamental.
Elham A Hassan, Haidi K Ramadan, Ali A Ismael, Khaled F Mohamed, Madiha M El-Attar, Ihab Alhelali   +5 more
doaj   +1 more source

Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. [PDF]

, 2015
BackgroundBudesonide foam, a rectally administered, second-generation corticosteroid with extensive hepatic first-pass metabolism, is efficacious for the treatment of mild-to-moderate ulcerative proctitis and ulcerative proctosigmoiditis.AimThe aim of ...
Barrett, Andrew C, Bortey, Enoch, Bosworth, Brian, Forbes, William P, Golden, Pamela L, Gordon, Glenn L, Rolleri, Robert L, Rubin, David T, Sale, Mark E, Sandborn, William J, Zakko, Salam   +10 more
core   +3 more sources

Acute Myeloid Leukemia (AML): The Role of Intensive Induction Chemotherapy [PDF]

International Journal of Hematology-Oncology and Stem Cell Research, 2004
Intensive induction therapy-in acute myeloid leukemia (AML), as in some other systemic malignancies- is a strategy fundamentally different from post-remission strategies.
Thomas Büchner, Wolfgang Hiddemann, Wolfgang E. Berdel, Bernhard Wörmann, Helmut Löffler, Claudia Schoch, Torsten Haferlach, Wolf-Dieter Ludwig, Georg Maschmeyer, Eva Lengelder, Peter Staib, Reinhard Andreesen, Leopold Balleisen, Detlef Haase, Hartmut Eimermacher, Andrea Schumacher, Carlo Aul, Herbert Rasche, Jens Uhlig, Andreas Grüneisen, Hans Edgar Reis, Joachim Hartlapp, Wolf-Dietrich Hirschmann, Hans-Josef Weh, Hermann-Josef Pielken, Winfried Gassmann, Maria-Cristina Sauerland, Achim Heinecke for the German AML Cooperative Group   +27 more
doaj   +2 more sources

Successful treatment of idiopathic retroperitoneal fibrosis with combined immunosuppressive therapy [PDF]

Vojnosanitetski Pregled, 2019
Background/Aim. Idiopathic retroperitoneal fibrosis (IRF) is characterized by the fibroinflammatory periaortic tissue that affects the ureters, causing obstructive nephropathy and variable impairment of renal function.
Obrenčević Katarina, Petrović Dejan, Aleksić Predrag, Petrović Marijana, Rančić Nemanja, Jovanović Dragan, Nikolić Bojan, Mijušković Mirjana, Vavić Neven, Ignjatović Ljiljana, Maksić Đoko   +10 more
doaj   +1 more source